Koppers Management Meeting with Financial Community in Montreal and Toronto

Aptoide Returns to Google Play After More Than a Decade, Opening a New Chapter for Competition on Android

TransMedia Group Plans to Sculpt Artful Publicity Highlighting Works of Israeli Sculptor Shafir Abrahamov

TransMedia Group to Spotlight Blanca Perper Greenstein as Laws of Life Expands Into a National Media Powerhouse

SoCalGas Introduces Updated Employee Uniforms to Improve Safety

Zensar Launches Quality Intelligence as a Strategic Service Line to Help Enterprises Build Trusted AI and Deliver Predictive Quality

Brayton Purcell LLP Releases The Best of From Dust to Verdict: Season 1, Part 1

ACL Digital Joins Forces with Hubbl to Accelerate AI Adoption for Enterprise Salesforce Customers

Protis Global Names Skye Miller and Isabel Cosby Co-Presidents, Launching Next Generation of Leadership

Globe Life Announces New Share Repurchase Authorization

Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio

U.S. Marine Corps Awards V2X Up to $500M Logistics Integration Support Contract

Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026

After Losing Her Young Son, One Mother Shares How Faith in God Sustained Her Family

AVANTIK NAMES JEFFREY WALDMAN CEO

Former Homicide Detective Releases Suspense Novel Inspired by Real Cases

Network Rail and CATALYST Complete Exploratory Pilot of Satellite-Enabled Risk Insights on the Wessex Route

Network Rail y CATALYST finalizan un proyecto piloto exploratorio en la ruta Wessex

Network Rail und CATALYST schließen exploratives Pilotprojekt zur satellitengestützten Risikoanalyse auf der Wessex-Strecke ab

Network Rail et CATALYST achèvent un projet pilote exploratoire portant sur l'analyse des risques liés aux informations satellitaires sur la ligne du Wessex

CAMTEK ANNOUNCES RESULTS FOR THE SECOND QUARTER OF 2026

Aurora, a Global Leader in Medical Cannabis, Announces Results of 2026 Annual General Meeting

Ascletis Announces Initiation of Two Phase I Studies in U.S. for the Treatment of Obesity: ASC36 Once-Monthly Injection, an Amylin Receptor Peptide Agonist, and ASC36_35FDC Once-Monthly Injection, a Co-Formulation of ASC36 and GLP-1R/GIPR Peptide Agonist ASC35

Shoulder Innovations Promotes Jon Osborne to Chief Commercial Officer

Twain Financial Partners Closes Inaugural Securitized Letter of Credit Facility and Initial Transaction Supporting a Utility-Scale Battery Storage Project

Ceva, Inc. Announces Second Quarter 2026 Financial Results

CSTS and Chelsea Football Club Launch Strategic Partnership to Deliver Unforgettable Football Experiences in Hong Kong

New Episode of Advancements Airing on Saturday, August 15th @8:00 pm ET.

Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001

Western Midstream Announces Second-Quarter Post-Earnings Interview with Chief Financial Officer, Kristen Shults and Participation in Upcoming Investor Conferences